This study involves people with hyperlipidemia, which is a condition where there are high levels of fats, including cholesterol, in the blood. The study will test a medication called MK-0616, which contains the active substance enlicitide chloride, given together with another medication called rosuvastatin. Rosuvastatin is a medicine that helps lower cholesterol levels and is already used in medical practice. Some participants will receive the actual medications while others will receive placebo, which is an inactive treatment that looks like the real medication but contains no active medicine.

The purpose of the study is to compare how well enlicitide combined with rosuvastatin works compared to placebo in lowering cholesterol levels, specifically a type of cholesterol called low-density lipoprotein cholesterol, in the blood after eight weeks of treatment. The study will also look at the safety of this combination of medications by monitoring any unwanted effects that may occur during the treatment period.

Participants in this study will take the study medications by mouth in the form of film-coated tablets for up to twelve months. During the study, measurements will be taken at different time points, particularly at week eight and week twelve, to see how the cholesterol levels change from the beginning of the study. The study will also measure other types of fats in the blood and count how many participants reach certain target cholesterol levels. The study is expected to start enrolling participants in late 2025 and continue until early 2027.